Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chromatin-associated YTHDC1 coordinates heat-induced reprogramming of gene expression.
Timcheva K, Dufour S, Touat-Todeschini L, Burnard C, Carpentier MC, Chuffart F, Merret R, Helsmoortel M, Ferré S, Grézy A, Couté Y, Rousseaux S, Khochbin S, Vourc'h C, Bousquet-Antonelli C, Kiernan R, Seigneurin-Berny D, Verdel A. Timcheva K, et al. Cell Rep. 2022 Dec 13;41(11):111784. doi: 10.1016/j.celrep.2022.111784. Cell Rep. 2022. PMID: 36516773 Free article.
Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer.
Heylen E, Verstraete P, Van Aerschot L, Geeraerts SL, Venken T, Timcheva K, Nittner D, Verbeeck J, Royaert J, Gijbels M, Uyttebroeck A, Segers H, Lambrechts D, Cools J, De Keersmaecker K, Kampen KR. Heylen E, et al. Among authors: timcheva k. Br J Cancer. 2023 May;128(10):1862-1878. doi: 10.1038/s41416-023-02216-y. Epub 2023 Mar 17. Br J Cancer. 2023. PMID: 36932191 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, Taushanova-Hadjieva MS, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP. Dodova RI, et al. Among authors: timcheva kv. BMC Cancer. 2017 Mar 16;17(1):195. doi: 10.1186/s12885-017-3188-6. BMC Cancer. 2017. PMID: 28302092 Free PMC article. No abstract available.
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, -Hadjieva MST, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP. Dodova RI, et al. Among authors: timcheva kv. BMC Cancer. 2015 Jul 17;15:523. doi: 10.1186/s12885-015-1516-2. BMC Cancer. 2015. PMID: 26183948 Free PMC article.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
14 results